Drug interactions
Indacaterol-glycopyrronium + Toremifene
Severity: Moderate
Indacaterol-glycopyrronium and Toremifene: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Toremifene prolongs the QT interval in a dose-related manner, and indacaterol, a beta-2 agonist, can also affect cardiac repolarization, particularly with hypokalemia. Combined use may raise the risk of torsades de pointes, especially in patients with other risk factors.
What this interaction means in plain words
Indacaterol-glycopyrronium and Toremifene can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Indacaterol-glycopyrronium belongs to Respiratory; Toremifene belongs to Endocrine.
Why it happens
Additive QT prolongation, with beta-2 agonist-induced hypokalemia and tachycardia adding to toremifene's effect on cardiac repolarization.
What to do
Obtain a baseline ECG and correct potassium and magnesium before starting. Monitor the QTc and avoid the combination in patients with congenital long QT syndrome or other QT-prolonging therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Indacaterol-glycopyrronium and Toremifene, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Other interactions of Toremifene
- Amiodarone + Toremifene Contraindicated
- Dronedarone + Toremifene Contraindicated
- Nilotinib + Toremifene Contraindicated
- Pimozide + Toremifene Contraindicated
- Quinidine + Toremifene Contraindicated
- Ribociclib + Toremifene Contraindicated
Frequently asked questions
Can I take Indacaterol-glycopyrronium with Toremifene?
MediHelp rates the interaction as moderate. Indacaterol-glycopyrronium and Toremifene can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Toremifene prolongs the QT interval in a dose-related manner, and indacaterol, a beta-2 agonist, can also affect cardiac repolarization, particularly with hypokalemia. Combined use may raise the risk of torsades de pointes, especially in patients with other risk factors.
How serious is the interaction between Indacaterol-glycopyrronium and Toremifene?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain a baseline ECG and correct potassium and magnesium before starting. Monitor the QTc and avoid the combination in patients with congenital long QT syndrome or other QT-prolonging therapy.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
